Ziihera Prices, Coupons, Copay Cards & Patient Assistance
Ziihera (zanidatamab) is a member of the HER2 inhibitors drug class and is commonly used for Biliary Tract Tumor.
The cost for Ziihera hrii 300 mg intravenous powder for injection is around $7,600 for a supply of 2 powder for injection, depending on the pharmacy you visit. Quoted prices are for cash-paying customers and are not valid with insurance plans. This price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
Ziihera prices
Intravenous Powder For Injection
hrii 300 mg
Ziihera intravenous powder for injection
from $7,600.07
for 2 powder for injection
| Quantity | Per unit | Price |
|---|---|---|
| 2 | $3,800.04 | $7,600.07 |
Important: When there is a range of pricing, consumers should normally expect to pay the lower price. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Drugs.com Printable Discount Card
The free Drugs.com Discount Card works like a coupon and can save you up to 80% or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions.
Print Free Discount CardNote: This is a drug discount program, not an insurance plan. Valid at all major chains including Walgreens, Target, WalMart Pharmacy, Duane Reade and 65,000 pharmacies nationwide.
Ziihera Coupons, Copay Cards and Rebates
Ziihera offers may take the form of printable coupons, rebates, savings or copay cards, trial offers, or free samples. Certain offers may be printable from a website while others may require registration, completing a questionnaire, or obtaining a sample from a medical professional.
Ziihera Savings Card
Eligible commercially insured patients may only pay $10 per prescription by enrolling in JazzCares.
- Applies to:
- Ziihera
- Number of uses:
- Per length of program
Form more information phone: 833-533-5299 or Visit website
Patient Assistance & Copay Programs for Ziihera
Patient assistance programs (PAPs) are typically sponsored by pharmaceutical companies and offer cost-free or discounted medicines, as well as copay programs, to individuals with low income or those who are uninsured/under-insured and meet specific criteria. Eligibility requirements for each program may vary.
Provider: Patient Access Network Foundation (PAN)
Eligibility requirements:- *See Additional Information section below
- Between 400-500% of FPL
- FDA Approved Diagnosis - See Program Website for Details
- Must reside and receive treatment in US
- *Patients must have health insurance and their insurance must cover the qualifying medication for which they seek assistance. Call for most recent medications as the list is subject to change and the medication for which you are seeking assistance must treat the disease directly. Note: All new enrollment is now done electronically or over the phone. Contact program for details.
- Ziihera (zanidatamab-hrii) Injection for Intravenous use
More information please phone: 866-316-7263 Visit Website
Provider: JazzCares: Ziihera
Eligibility requirements:- Must have no prescription coverage for needed medication
- At or below 400% of FPL
- FDA-approved diagnosis
- Must be a US resident and treated by a US licensed healthcare provider
- Eligibility determined on a case-by-case basis. Co-payment assistance, and patient assistance programs are available for eligible patients.
- Ziihera (zanidatamab-hrii) Injection for Intravenous use
More information please phone: 833-533-5299 Visit Website
Disclaimer: Medication pricing is sourced from a variety of providers. Pricing may vary significantly due to several factors including brand or generic status, insurance coverage, pharmacy choice, location, and manufacturer pricing policies. Prices are subject to change. For the most accurate and up-to-date information, always consult directly with your pharmacy or healthcare provider.
See also:
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Imfinzi
Imfinzi (durvalumab) is an immunotherapy used to treat types of lung cancer (NSCLC, SCLC), bile ...
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Pemazyre
Pemazyre is used to treat certain types of bile duct cancer and myeloid/lymphoid neoplasms ...
Pemigatinib
Pemigatinib systemic is used for cholangiocarcinoma, myeloid/lymphoid neoplasms
Ivosidenib
Ivosidenib systemic is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Durvalumab
Durvalumab (Imfinzi) is an immunotherapy used to treat lung cancer (NSCLC, SCLC) and other cancers ...
More about Ziihera (zanidatamab)
- Check interactions
- Compare alternatives
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- En español
